共 50 条
- [1] Efficacy and safety of PEGylated Recombinant Methionyl Human Soluble Tumor Necrosis Factor Receptor Type I; A phase 2 study in patients with rheumatoid arthritis.ARTHRITIS AND RHEUMATISM, 2003, 48 (09): : S121 - S121Sarzi-Puttini, PThomson, GSheldon, ERoschmann, RLiu, TLee, DSolinger, A
- [2] A phase 2 dose-finding study of PEGylated recombinant methionyl human soluble tumor necrosis factor type I in patients with rheumatoid arthritisJOURNAL OF RHEUMATOLOGY, 2005, 32 (12) : 2303 - 2310Furst, DEFleischmann, RKopp, ESchiff, MEdwards, CKSolinger, AMacri, M
- [3] Combination therapy with anakinra and PEGylated soluble tumor necrosis factor receptor type I in rheumatoid arthritis: A study of early clinical and synovial tissue responsesARTHRITIS AND RHEUMATISM, 2002, 46 (09): : S132 - S132Rooney, TMadigan, ADayer, JMFitzGerald, OGogarty, MGreenan, LVWright, NLawrence, EMiller, DEdwards, CKVeale, DJBresnihan, B
- [4] Combination benefit of treatment with recombinant human interleukin-1 receptor antagonist (IL-Ira) and pegylated recombinant human soluble tumor necrosis factor receptor type I (PEG sTNF-RI) in animal models of rheumatoid arthritis.ARTHRITIS AND RHEUMATISM, 1999, 42 (09): : S171 - S171Bendele, AMChlipala, ESRich, WREdwards, CK
- [6] Association of soluble tumour necrosis factor receptor II levels with mortality in rheumatoid arthritisRHEUMATOLOGY, 2005, 44 : I11 - I12Glossop, JRDawes, PTHassell, ABMattey, DL
- [7] Combination benefit of treatment with the cytokine inhibitors interleukin-1 receptor antagonist and PEGylated soluble tumor necrosis factor receptor type I in animal models of rheumatoid arthritisARTHRITIS AND RHEUMATISM, 2000, 43 (12): : 2648 - 2659Bendele, AMChlipala, ESScherrer, JFrazier, JSennello, GRich, WJEdwards, CK
- [8] Soluble tumour necrosis factor receptor treatment does not affect raised transforming growth factor β levels in rheumatoid arthritisANNALS OF THE RHEUMATIC DISEASES, 2002, 61 (03) : 254 - 256Drynda, SKühne, CKekow, J
- [9] The pharmacokinetics of subcutaneous injections of pegylated recombinant methionyl human soluble tumor necrosis factor type receptor (PEG sTNF-RI) in subjects with active rheumatoid arthritis.ARTHRITIS AND RHEUMATISM, 1999, 42 (09): : S79 - S79Martin, SWSommers, JSMacri, MJNewmark, RDJelsea-Maxwell, KTurner, SAFrazler, JLYoung, JDEdwards, CKDavis, MW
- [10] Polymorphism in the tumour necrosis factor receptor II gene is associated with circulating levels of soluble tumour necrosis factor receptors in rheumatoid arthritisArthritis Research & Therapy, 7John R GlossopPeter T DawesNicola B NixonDerek L Mattey